Recce Pharmaceuticals Provides Positive Update on Patients Treated with RECCE® 327 Under “Special Access Scheme”
Figure 1 Patient Case Study Example A Figure 2 Patient Case Study Example B Figure…
Figure 1 Patient Case Study Example A Figure 2 Patient Case Study Example B Figure…
Figure 1 Patient Case Study Example A Figure 2 Patient Case Study Example B Figure…
Tigris Trial Enrollment Reaches 71 Patients TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Spectral Medical…
Tigris Trial Enrollment Reaches 71 Patients TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — Spectral Medical…
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage…
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage…
Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with…
Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with…
Alimera Acquired U.S. Commercial Rights to YUTIQ® Landmark NEW DAY Study Completed Enrollment with over…
Alimera Acquired U.S. Commercial Rights to YUTIQ® Landmark NEW DAY Study Completed Enrollment with over…
DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the…
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the…
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven…
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven…
– Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or…
– Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or…
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line…
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line…